These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

656 related items for PubMed ID: 10889379

  • 1. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer.
    Zelefsky MJ, Hollister T, Raben A, Matthews S, Wallner KE.
    Int J Radiat Oncol Biol Phys; 2000 Jul 15; 47(5):1261-6. PubMed ID: 10889379
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer.
    Zelefsky MJ, Wallner KE, Ling CC, Raben A, Hollister T, Wolfe T, Grann A, Gaudin P, Fuks Z, Leibel SA.
    J Clin Oncol; 1999 Feb 15; 17(2):517-22. PubMed ID: 10080594
    [Abstract] [Full Text] [Related]

  • 3. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
    Merrick GS, Butler WM, Galbreath RW, Lief JH, Adamovich E.
    Int J Radiat Oncol Biol Phys; 2002 Mar 01; 52(3):664-73. PubMed ID: 11849788
    [Abstract] [Full Text] [Related]

  • 4. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
    Kollmeier MA, Stock RG, Stone N.
    Int J Radiat Oncol Biol Phys; 2003 Nov 01; 57(3):645-53. PubMed ID: 14529768
    [Abstract] [Full Text] [Related]

  • 5. Combined 3-dimensional conformal radiotherapy and transperineal Pd-103 permanent implantation for patients with intermediate and unfavorable risk prostate cancer.
    Singh A, Zelefsky MJ, Raben A, Lombardi D, Leibel SA.
    Int J Cancer; 2000 Oct 20; 90(5):275-80. PubMed ID: 11091351
    [Abstract] [Full Text] [Related]

  • 6. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
    Zelefsky MJ, Fuks Z, Hunt M, Lee HJ, Lombardi D, Ling CC, Reuter VE, Venkatraman ES, Leibel SA.
    J Urol; 2001 Sep 20; 166(3):876-81. PubMed ID: 11490237
    [Abstract] [Full Text] [Related]

  • 7. Risk group stratification in patients undergoing permanent (125)I prostate brachytherapy as monotherapy.
    Kwok Y, DiBiase SJ, Amin PP, Naslund M, Sklar G, Jacobs SC.
    Int J Radiat Oncol Biol Phys; 2002 Jul 01; 53(3):588-94. PubMed ID: 12062601
    [Abstract] [Full Text] [Related]

  • 8. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Kupelian P, Kuban D, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A.
    Int J Radiat Oncol Biol Phys; 2005 Feb 01; 61(2):415-9. PubMed ID: 15667961
    [Abstract] [Full Text] [Related]

  • 9. Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial.
    Martinez AA, Kestin LL, Stromberg JS, Gonzalez JA, Wallace M, Gustafson GS, Edmundson GK, Spencer W, Vicini FA.
    Int J Radiat Oncol Biol Phys; 2000 May 01; 47(2):343-52. PubMed ID: 10802358
    [Abstract] [Full Text] [Related]

  • 10. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A, Kuban D.
    Int J Radiat Oncol Biol Phys; 2005 Nov 01; 63(3):795-9. PubMed ID: 15925452
    [Abstract] [Full Text] [Related]

  • 11. Does hormonal manipulation in conjunction with permanent interstitial brachytherapy, with or without supplemental external beam irradiation, improve the biochemical outcome for men with intermediate or high-risk prostate cancer?
    Merrick GS, Butler WM, Galbreath RW, Lief JH, Adamovich E.
    BJU Int; 2003 Jan 01; 91(1):23-9. PubMed ID: 12614244
    [Abstract] [Full Text] [Related]

  • 12. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy.
    Potters L, Cha C, Oshinsky G, Venkatraman E, Zelefsky M, Leibel S.
    Cancer J Sci Am; 1999 Jan 01; 5(5):301-6. PubMed ID: 10526671
    [Abstract] [Full Text] [Related]

  • 13. Dose response in prostate cancer with 8-12 years' follow-up.
    Hanks GE, Hanlon AL, Epstein B, Horwitz EM.
    Int J Radiat Oncol Biol Phys; 2002 Oct 01; 54(2):427-35. PubMed ID: 12243818
    [Abstract] [Full Text] [Related]

  • 14. Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation.
    Vicini FA, Kestin LL, Martinez AA.
    Tech Urol; 2000 Jun 01; 6(2):135-45. PubMed ID: 10798815
    [Abstract] [Full Text] [Related]

  • 15. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer.
    Zelefsky MJ, Chan H, Hunt M, Yamada Y, Shippy AM, Amols H.
    J Urol; 2006 Oct 01; 176(4 Pt 1):1415-9. PubMed ID: 16952647
    [Abstract] [Full Text] [Related]

  • 16. Biochemical (prostate-specific antigen) relapse-free survival and toxicity after 125I low-dose-rate prostate brachytherapy.
    Khaksar SJ, Laing RW, Henderson A, Sooriakumaran P, Lovell D, Langley SE.
    BJU Int; 2006 Dec 01; 98(6):1210-5. PubMed ID: 17034501
    [Abstract] [Full Text] [Related]

  • 17. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome.
    Kupelian PA, Buchsbaum JC, Elshaikh MA, Reddy CA, Klein EA.
    Int J Radiat Oncol Biol Phys; 2003 Nov 01; 57(3):629-34. PubMed ID: 14529766
    [Abstract] [Full Text] [Related]

  • 18. Isotope selection for patients undergoing prostate brachytherapy.
    Cha CM, Potters L, Ashley R, Freeman K, Wang XH, Waldbaum R, Leibel S.
    Int J Radiat Oncol Biol Phys; 1999 Sep 01; 45(2):391-5. PubMed ID: 10487561
    [Abstract] [Full Text] [Related]

  • 19. Urinary morbidity with a modified peripheral loading technique of transperineal (125)i prostate implantation.
    Brown D, Colonias A, Miller R, Benoit R, Cohen J, Arshoun Y, Galloway M, Karlovits S, Wu A, Johnson M, Quinn A, Kalnicki S.
    Int J Radiat Oncol Biol Phys; 2000 May 01; 47(2):353-60. PubMed ID: 10802359
    [Abstract] [Full Text] [Related]

  • 20. Prostate cancer with large glands treated with 3-dimensional computerized tomography guided pararectal brachytherapy: up to 8 years of followup.
    Koutrouvelis PG, Lailas N, Katz S, Sehn J, Gil-Montero G, Khawand N.
    J Urol; 2003 Apr 01; 169(4):1331-6. PubMed ID: 12629354
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.